In-silico design of new enalapril analogs (ACE inhibitors) using QSAR and molecular docking models
Authors:
- Jhon Alex Gonzalez AmayaJAJhon Alex Gonzalez Amaya
- Daniella Zambrano CabreraDCDaniella Zambrano Cabrera
- Alejandra Mojica MatallanaAMAlejandra Mojica Matallana
- Karen González ArevaloKAKaren González Arevalo
- James Guevara-PulidoJames Guevara-Pulido
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 19
Abstract
No abstract availableKeywords
Funding Information
- Universidad El Bosque
This publication has 22 references indexed in Scilit:
- Angiotensin-Converting Enzyme Inhibitors Induce CoughTurkish Thoracic Journal, 2019
- Deep Learning and Virtual Drug ScreeningFuture Medicinal Chemistry, 2018
- Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 ContinentsHypertension, 2017
- ACE Inhibitor-Induced Angioedema of the Small Bowel: A Case Report and Review of the LiteratureJournal of Pharmacy Practice, 2017
- Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysisAnalytical Biochemistry, 2016
- How to design a potent, specific, and stable angiotensin-converting enzyme inhibitorDrug Discovery Today, 2014
- Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockersImmunopharmacology and Immunotoxicology, 2013
- A new QSAR model, for angiotensin I-converting enzyme inhibitory oligopeptidesFood Chemistry, 2013
- 3D-QSAR Studies on Angiotensin-Converting Enzyme (ACE)Inhibitors: a Molecular Design in Hypertensive AgentsBulletin of the Korean Chemical Society, 2005
- Use of ACE Inhibitors in the Treatment of Cardiovascular DiseaseAmerican Pharmacy, 1992